FDA Approves New Twice a Week Diabetes Drug
Submitted by Satish Karat on Mon, 01/30/2012 - 12:37
It has been recently revealed in a report that the new drug developed by Amylin Pharmaceutical Company from San Diego has been given approval by the Food and Drug Administration in the U. S.
It has been further revealed that with the mere decision of the approval being out, the shares of the firm have seen a rise of 17% recently.
New Diabetes Drug Approved for Once a Week Dosage
Submitted by Davell Wilkins on Sat, 01/28/2012 - 11:13
It has been recently revealed in a report that the new proposal of Amylin Pharmaceutical company for a more convenient and novel type of diabetes drug has been approved by the Food and Drug Administration.
No Increased Risk of Cardiovascular Events Seen in Exenatide Clinical Data Analysis
Submitted by Jason Ramsey on Sat, 03/28/2009 - 23:06
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. announced that their diabetes drug Byetta (exenatide) was not linked to increased cardiovascular events, strokes or other cardiovascular side effects.
Latest News
|
|
|
|
|
|
|
|
|
|
|
|
